Researchers observed inequities in receipt of first-line preferred therapies among a cohort of patients with chronic ...

Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL ...

Chronic lymphocytic leukemia (CLL) is due to the unremitting accumulation of neoplastic CD5 + B cells in blood, bone marrow, and lymphoid tissues. The prognosis of patients with this form of leukemia ...

Defects in the DNA damage sensors, particularly in the ataxia telengiectasia mutated (ATM)/TP53 pathways, confer resistance to standard chemotherapic agents used in CLL [4] that inflict DNA damage ...

AstraZeneca (LSE: AZN) has received European approval for a fixed-duration regimen of Calquence (acalabrutinib) in ...

Although there has been steady uptake of targeted therapies across LOTs, unmet need persists for patients with CLL/SLL who receive later LOTs. The time to the next treatment decreased with each LOT, ...

Lisocabtagene maraleucel significantly improved responses rates and survival outcomes among patients with relapsed or refractory chronic lymphocytic leukemia, according to findings presented at ASCO ...

Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

HealthDay News — For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL), statin use is associated with improved survival, regardless of treatment employed, according ...

The latest news from ASCO 2025 focusing on CLL including abstracts, features, and helpful conference information.